Ataxin-3 plays a role in mouse myogenic differentiation through regulation of integrin subunit levels by Costa, Maria do Carmo et al.
Ataxin-3 Plays a Role in Mouse Myogenic Differentiation
through Regulation of Integrin Subunit Levels
Maria do Carmo Costa1,2, Fernanda Bajanca1¤, Ana-Joa˜o Rodrigues1, Ricardo J. Tome´3, Garry Corthals4,
Sandra Macedo-Ribeiro3, Henry L. Paulson2, Elsa Logarinho1,3, Patrı´cia Maciel1*
1 Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal, 2Department of Neurology, University of Michigan,
Ann Arbor, Michigan, United States of America, 3 Instituto de Biologia Molecular e Celular (IBMC), Universidade do Porto, Porto, Portugal, 4 Turku Center for
Biotechnology, Turku, Finland
Abstract
Background: During myogenesis several transcription factors and regulators of protein synthesis and assembly are rapidly
degraded by the ubiquitin-proteasome system (UPS). Given the potential role of the deubiquitinating enzyme (DUB) ataxin-
3 in the UPS, and the high expression of the murine ataxin-3 homolog in muscle during embryogenesis, we sought to define
its role in muscle differentiation.
Methodology/Principal Findings: Using immunofluorescence analysis, we found murine ataxin-3 (mATX3) to be highly
expressed in the differentiated myotome of E9.5 mouse embryos. C2C12 myoblasts depleted of mATX3 by RNA interference
exhibited a round morphology, cell misalignment, and a delay in differentiation following myogenesis induction.
Interestingly, these cells showed a down-regulation of a5 and a7 integrin subunit levels both by immunoblotting and
immunofluorescence. Mouse ATX3 was found to interact with a5 integrin subunit and to stabilize this protein by repressing
its degradation through the UPS. Proteomic analysis of mATX3-depleted C2C12 cells revealed alteration of the levels of
several proteins related to integrin signaling.
Conclusions: Ataxin-3 is important for myogenesis through regulation of integrin subunit levels.
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Introduction
Myogenesis is the process of differentiation of muscle precursor
cells (MPCs) into multinucleated myotubes that mature into
myogenic fibers [1,2]. This is strictly regulated by two families of
transcription factors: the myogenic regulatory factors (MRFs), and
the myocyte enhancer-binding factor 2 (MEF2). The MRFs,
consisting of Myf5, MyoD, MRF4 and myogenin, usually forming
heterodimers with ubiquitous E-proteins (E12 or E47) [3], act in
combination with MEF2 transcription factor family to activate
many muscle-specific genes [4].
For successful myogenesis many cellular processes must occur,
directed by transcriptional regulation by MRFs and MEF2,
intracellular signaling, cell migration, cell-cell interaction, and cell
connections with the extracellular matrix (ECM). Integrins are
important players in these processes. These transmembrane cell
surface ECM receptors form heterodimers composed of an a and
b subunits [5]. Clustering of integrins upon matrix binding
provides a bidirectional crosstalk between the inside and outside
signaling. As a consequence of cell-matrix adhesions, several
proteins are recruited to the adhesion complexes, activating
signaling cascades that control cytoskeletal organization, gene
regulation, and diverse cellular processes and functions [6]. In
vitro and in vivo studies in avian and rodent species showed that
a4b1, aVb1, a5b1, a6b1, and a7b1 integrins are the major
players in skeletal muscle development [7].
It is crucial that the synthesis, degradation, and assembly of many
proteins be closely regulated at each phase of muscle development.
Many transcription factors and other proteins participating in the
aforementioned processes are rapidly degraded by the UPS,
including MyoD [8], Myf5 [9], myogenin [10], Pax3 [11], Id
proteins [12], b-catenin [13,14], and a5 integrin subunit [15].
The reversal of ubiquitination, catalyzed by deubiquitinating
(DUB) enzymes, is equally important in several cellular processes.
So far, only two DUBs, UBP45 and UBP69, have been implicated
in myogenesis but their specific role is still unknown [16]. Thus, it
remains to be determined how the removal of ubiquitin from
certain proteins by DUBs contributes to muscle development.
Ataxin-3 (ATX3) is the best characterized member among a
small new subclass of DUBs [17]. DUB activity in ATX3 is
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conferred by the N-terminal josephin domain, carrying the
essential Cysteine 14 (C14) residue responsible for its protease
activity [18,19,20]. Several lines of evidence suggest that ATX3
may function in the UPS: (1) it binds and hydrolyses polyubiquitin
chains in vitro [21,22,23,24]; (2) it interacts with ubiquitin (Ub) and
NEDD8, a ubiquitin-like (UBL) protein that regulates the activity
of E3 ligases [25]; and (3) it associates with the proteasome
through interactions with p45 (an ATPase subunit of the 19S
proteasome subunit) [26], VCP/p97 (an AAA ATPase important
for the shuttling of many polyubiquitinated proteins to the
proteasome) [27,28], and Ubxn-5 [29].
ATX3, an ubiquitously expressed protein that contains a
polyglutamine (polyQ) tract near its C-terminus that is neighbored
by two or three ubiquitin interacting motifs (UIMs) [24],
depending on the protein isoform. In humans, this polyQ segment
usually consists of 12–44 glutamines, but it is expanded to ,60–87
glutamines in Machado-Joseph disease (MJD), also known as
spinocerebellar ataxia type 3 (SCA3). MJD is the most common
dominantly inherited cerebellar ataxia in the world [30]. The
neurological phenotype in MJD, which can range widely, has been
classified into at least three subtypes with characteristic features:
cerebellar ataxia with ophthalmoparesis and pyramidal tract signs
(type II), with additional extrapyramidal signs (type I), or with
distal muscular atrophy (type III) [31]. In early descriptions of
MJD, muscle alterations were observed although studies of muscle
involvement have been limited [31,32,33].
ATX3 is a highly conserved protein throughout evolution.
We previously observed that the murine homolog (mATX3)
exhibits ubiquitous expression, including during embryonic
development [34]. Furthermore, mATX3 is highly expressed
in muscle cells from embryonic development through adult
ages, and its transcription is activated to a great extent in
muscle-differentiated P19 cells [34]. To date, besides a potential
involvement of ATX3 in transcriptional repression, DNA repair
[35], and in endoplasmic reticulum associated protein degra-
dation (ERAD) [28], no other cellular functions for ATX3 are
known, and no physiological substrates for its DUB activity
have been identified.
In this study we assessed the role of mATX3 in muscle
differentiation. We found that mATX3 is strongly expressed in the
early myotome of E9.5 mouse embryos, and it colocalizes with
myosin in differentiated myogenic fibers. We found that mATX3
depletion in C2C12 cells perturbs the phenotypical response to
differentiation induction, such as cell alignment and elongation,
and also cellular proliferation. In addition, we observed that levels
of a5 and a7 integrin subunits, as well as many other proteins
implicated in the integrin signaling pathway, were altered in
mATX3-depleted cells. Altogether, our data suggest that mATX3
is contributing to muscle differentiation by preventing the
degradation of integrin subunits through the UPS.
Results
Ataxin-3 is highly expressed in the early differentiated
myotome and in muscle fibers
To characterize the expression of mATX3 in the developing
muscle, we performed double immunofluorescence labeling for
mATX3 and myogenic markers in mouse embryo sections from
E9.5 to E18.5.
Although being broadly expressed, detected in the dermomyo-
tome, and throughout the whole extent of the myotome, mATX3
is surprisingly up-regulated at E9.5 in elongated myogenin-positive
cells (Figure 1A). This expression pattern is also observed at in the
differentiated myotome at E11.5 (Figure 1B).
Immunoreactivity was also detected in muscle fibers analyzed
later on (E14.5, E18.5, and adult) with no predominance in muscle
type (Figure 1C, D, E).
The expression pattern suggests that mATX3 is present in all
stages of myogenesis, with highest immunoreactivity in earlier
stages of differentiation. Therefore, ATX3 may be implicated in
muscle development.
Ataxin-3 depletion perturbs the phenotype of
differentiating C2C12 cells
To study the role of mATX3 in myogenic differentiation we
transfected C2C12 myoblast cells with siRNA targeting the Mjd
transcript, and induced their differentiation by switching from
growth medium (GM) to a serum-limited differentiation medium
(DM). The expression levels of mATX3 in Mjd siRNA-depleted
cell extracts collected over time were analyzed by immunoblotting
and compared with controls (mock transfection). The choice of the
ideal time point to induce differentiation (Day 0) was based on the
maximum suppression of mATX3 expression obtained two days
after Mjd siRNA transfection (Day -2), with a reduction to about
18% of normal mATX3 levels (Figure 2A, B). In a pattern
consistent with a putative role in myogenic differentiation,
mATX3 levels in C2C12 control cells increase upon induction
of differentiation at Day 0 (Figure 2A, B, mock).
After induction of differentiation (Day 0 to Day 5), Mjd siRNA-
transfected cells were phenotypically different from mock-trans-
fected cells: cell shape was rounder, with very thin cell extensions
and extensive cell-cell misalignment (Figure 2C). At Day 5 the
mATX3-depleted cells showed a very immature cytoskeleton, with
myosin-containing filaments fragmented in the cytoplasm that
failed to elongate as their control counterparts (Figure 2D). To
exclude the possibility that the use of a dicer-generated pool of Mjd
siRNAs might be interfering with other similar mRNAs, we
analyzed the levels of the transcripts encoding the josephin-
domain proteins (Josd1 and Josd2). Quantitative real-time PCR
revealed no significant differences for these transcripts between
mock and Mjd siRNA transfected C2C12 cells at Days 0 and 1 of
differentiation (Figure S1). These results suggest that the
phenotype observed in C2C12 cells transfected with Mjd siRNA
was specifically due to mATX3 knockdown, and that this protein
is required during the differentiation process. Consistently, at Day
5, when mATX3 levels were restored to the levels of Day -2, the
phenotype started to revert (Figure 2C).
To determine whether the mATX3-depletion phenotype was
due to direct alteration of the myogenic transcriptional program,
we analyzed the levels of the myogenic regulatory factors MyoD
(Figure 2A) and myogenin (not shown) by immunoblotting. No
differences were observed between Mjd siRNA and mock-
transfected differentiated cells, suggesting that mATX3 does not
perturb the onset of the myogenic program but has instead
downstream targets.
Ataxin-3 regulates a5 and a7 integrin subunit levels
during myogenic differentiation
Providing a link between the extracellular matrix and the cell
cytoskeleton, integrins play a critical role for the cytoskeletal
modifications induced by myogenic differentiation. We sought to
determine whether the abnormal phenotype of mATX3-depleted
cells could be due to a perturbation on integrin levels and analyzed
the expression pattern of two integrin subunits known to play a
role in myogenesis: a5 integrin subunit and a7 integrin subunit.
Immunoblotting detection of a5, a7(A+B) and a7B integrin
subunits in mock transfected C2C12 cells revealed that while the
Ataxin-3 and Myogenesis
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Figure 1. Mouse ataxin-3 (mATX3) is highly expressed in the early differentiated cells in the myotome,as well as in embryonic and
adult muscle fibers. Maximum projection of confocal optical z-series from sagittal 15 mm sections of E9.5 (A), E11.5 (B), E14.5 (C) and E18.5 (D)
mouse embryos labeled for mATX3 and the myogenic differentiation markers myogenin (A, B) or myosin (C, D). (A) mATX3 (green, arrows) is highly
upregulated in differentiated myogenin-positive cells (red) when comparing with younger myogenin-negative cells in the myotome (arrowheads). (B)
strong staining for mATX3 (green, arrows) remains present in E11.5 elongated myogenin-positive myocytes (red). (C) E14.5 intercostal muscle
Ataxin-3 and Myogenesis
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a5 subunit shows an immediate increase upon differentiation, and
the a7 subunits increase more progressively (Figure 3A, B), which
is in accordance with previously described expression patterns
[36]. In contrast, we observed a decrease in the expression of both
integrin subunits in Mjd siRNA-treated cells (Figure 3A, B).
Interestingly, the a7 subunits levels were consistently maintained
low until Day 5, while the a5 subunit levels decreased significantly
from Day 0 to Day 2, and then started to increase at Day 3 until
Day 5. This suggests that the a5 integrin subunit may be directly
dependent on the levels of mATX3, registering a recovery as Mjd
siRNA loses effect (see Figure 2 A, B). In contrast, the a7 integrin
subunit levels were not able to recover during the experiment time
course, suggesting that the relation with mATX3 may be indirect
or that the effect of mATX3 depletion is less reversible in this case.
The results obtained by immunoblotting were confirmed by co-
immunostaining of mATX3 and a5 integrin subunit at Days 0 and
3 and mATX3 and a7 integrin subunit at Day 3 in Mjd siRNA-
transfected C2C12 cells (Figure 4). Despite some increase of
mATX3 levels at Day 3, comparing to Day 0 and Day 1, the Mjd
siRNA cells still exhibited round shape, cell-cell misalignment and
decreased amounts of a5 and a7 integrin subunits (Figure 4).
To define whether mATX3 affects the expression of a5 and a7
integrin subunits at the mRNA or protein level, we extracted total
RNA from mock and Mjd siRNA-transfected undifferentiated
(Day 0) and differentiated cells at Day 1 (the days of maximal
depletion of Mjd transcript), and performed quantitative real-time
RT-PCR to determine the amounts of the respective mRNAs
(Itga5 and Itga7). No significant differences between mock and
siRNA-depleted cells were observed for Itga5 or Itga7 mRNA levels
(Figure 3C), suggesting that the effect on a5 and a7 integrin
subunit expression occurs at the protein level.
Ataxin-3 interacts with a5 integrin subunit and represses
its degradation
Several observations led us to consider the possibility that
mATX3 might regulate the a5 integrin subunit degradation
through the UPS: i) the expression profile of a5 integrin subunit
mirrors that of mATX3 in mock- and Mjd siRNA-transfected
C2C12 cells undergoing differentiation, ii) Itga5 transcript levels
remain unaltered in the mATX3-depleted cells, iii) ATX3 is a
DUB, and iv) a5 integrin subunit levels are known to be regulated
by the UPS [15]. Therefore, we first tested mATX3 for DUB
activity. We expressed several recombinant proteins, and isolated
the monomeric protein by gel filtration chromatography (Figure
S2 and Materials and methods S1) [37]. Both the entire protein
(mATX3), and the josephin domain (mATX3:jos) by itself, were
able to cleave the fluorogenic substrate ubiquitin-AMC, and this
activity was inhibited by mutation of the active site cysteine in
mATX3:C14A and mATX:jos:C14A proteins (data not shown).
As shown for other homologues, mATX3, specifically its josephin
domain (mATX3:jos), is able to cleave either K48 or K63-linked
polyubiquitin chains, the cysteine 14 residue being essential for this
activity (Figure S2).
Considering the possibility that a5 integrin subunit might be a
substrate of mATX3, and that its deubiquitination could act to
prevent its degradation through the UPS, we tested the interaction
between these two proteins. In GST-pull down assays employing
recombinant GST:mATX3 and total protein extracts from E16.5
mouse embryo, endogenous a5 integrin subunit co-precipitated
with GST-mATX3 (Figure 5), confirming that a direct or indirect
interaction between ATX3 and a5 integrin subunit occurs during
mouse embryonic development. The 90KDa band pulled by
GST:mATX3 and detected with the anti-a5 integrin antibody
might correspond to a cleaved form of the protein.
To determine if mATX3 acts to inhibit a5 integrin subunit
degradation during myogenesis, we assessed the levels of
endogenous a5 integrin subunit upon protein synthesis inhibition
with cycloheximide in C2C12 GFP:mATX3 overexpressing cells.
The a5 integrin subunit was more abundant in these cells than in
control GFP-transfected cells or in GFP::mATX3C14 (DUB
catalytic mutant) overexpressing cells (all presenting the same
levels of endogenous mATX3) (Figure 6A, B), indicating that
mATX3 is able to stabilize this protein and prolong its half-life.
Indeed, we verified by denature-renature immunoprecipitation
assays an increase of high molecular weight (HMW) ubiquitinated
a5 integrin subunit species upon UPS inhibition with MG132 in
mATX3-depleted cells (Figure 6C), which implies that mATX3 is
repressing its proteolysis at the UPS level. In contrast, cells
overexpressing mATX3 show decreased levels of ubiquitinated a5
integrin subunit species, but not cells overexpressing the catalytic
mutant mATX3C14A that showed a similar pattern to the empty
vector-transfected cells (Figure 6C).
Proteomic analysis of ataxin-3 depleted-cells leads to
changes in the integrin signaling pathway
Aiming to identify proteins required for muscle differentiation,
the expression of which is altered upon mATX3 repression, we
performed a large-scale proteomic analysis of undifferentiated Mjd
siRNA-treated C2C12 cells (Day 0). Two independent samples of
total proteins extracted from C2C12 cells (mock and Mjd siRNA
transfections) were labelled using the iTRAQ technology,
separated by isoelectric focusing, and analyzed by LC-ESI-MS/
MS. The average number of proteins detected per sample was
1634 proteins. We considered proteins with altered expression
levels to be those presenting changes of 20% or more of the
normal levels (1.2,ratio,0.8) and significant p-value. At Day 0,
when the levels of mATX3 were maximally reduced in Mjd siRNA
transfected cells, a total of 106 proteins were found to be altered
(Table S1). Using the Ingenuity Pathways AnalysisH software,
these proteins were grouped into six functional networks
(according to the software annotation) (Table S1). In agreement
with the phenotype observed, two of these networks were ‘‘Skeletal
and muscular system development and function/Tissue morphol-
ogy/Cancer’’ and ‘‘Cellular development/Embryonic develop-
ment/Cellular assembly and organization’’.
To identify the effect of mATX3 depletion in the integrin
signaling pathway we overlaid the proteins altered in this condition
with the integrin signaling canonical pathway using the above
mentioned software. Interestingly, three proteins involved in the
integrin signal transduction cascade that specifically leads to
cytoskeleton rearrangements and cell motility showed altered
levels in the mATX3-depleted cells: two subunits of the actin
related protein 2/3 (Arp2/3) complex, Arpc2 (21.3-fold) and
Arpc3 (+1.3-fold); and the GTPase Cdc42, which, in turn,
activates the Arp2/3 complex (+1.3-fold) (Table S1). In addition,
two structural components of the cytoskeleton, plectin 1 (Plec1)
and vimentin (Vim), were down-regulated, 21.3 and 21.3-fold,
respectively (Table S1). The altered levels of Arpc2, Arpc3, Cdc42,
showing a fiber-like labeling pattern of mATX3 (green) colocalising with myosin-positive fibers (red). (D) mATX3 (green, arrows) remains strongly
expressed at late fetal stages in myosin-positive fibers (red). (E) mATX3 (green) is expressed in adult myosin fibers (red). (1) mATX3 staining, (2) myosin
(MHC) or myogenin labeling, (3) triple overlay of mATX3, myogenic marker, and DAPI. Scale bars represent 80 mm.
doi:10.1371/journal.pone.0011728.g001
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Figure 2. Expression profile of mATX3 during C2C12 differentiation and phenotype of mATX3-depleted cells by Mjd siRNA
transfection. Cells were transfected at Day -2 and maintained in growth medium (GM) for 48 hrs (Day 0), then the medium was replaced by
differentiation medium (DM) and changed every day until Day 5. (A) Whole cell extracts of undifferentiated (Day -2 and Day 0) and differentiated cells
(Day 1 to Day 5) were analyzed for mATX3, MyoD and a-tubulin in mock and Mjd siRNA transfected cells. The amounts of ataxin-3 and MyoD were
determined by immunoblotting. The myogenic factor MyoD is not a target of mATX3. Both mock and Mjd siRNA-transfected cells show that this MRF
is upregulated upon differentiation. (B) Relative band density of mATX3 in each day (comparing with Day -2) shows that the Mjd siRNA has maximum
efficiency two days after transfection (Day 0). The results were normalized for a-tubulin and correspond to the average of three independent
transfections 6 SEM (error bars). * statistical significance p,0.05 using Student t-test. (C) Phenotype of the Mjd siRNA C2C12 cells during
differentiation. At Day 0 and Day 1, when mATX3 depletion is higher, the Mjd siRNA cells show extensive cell-cell misalignment, and rounder shape
compared to mock-transfected cells. Although the mATX3 levels were partially restored at Day 5, the knocked-down cells still present some
misalignment. (D) The maximum projection of confocal optical z-series images of mATX3 and myosin double-stained cells at differentiation Day 5. In
contrast to mock control cells that show a well organized myosin cytoskeleton (arrows), mATX3-depleted cells show an abnormally fragmented
myosin staining with a very short filament pattern. (1) mATX3 staining, (2) myosin (MHC) labeling, (3) triple overlay of mATX3, myogenic marker, and
DAPI (DNA marker). Scale bars represent 10 mm.
doi:10.1371/journal.pone.0011728.g002
Ataxin-3 and Myogenesis
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Plec1 and Vim in the mATX3-depleted cells were confirmed by
immunoblotting (Figure 7A, B). In fact, the fold change values of
these proteins found in the proteomic analysis and in the
immunoblotting were very similar, except for Vim that showed a
higher fold decrease in the immunoblotting detection (Figure 7B
and Table S1). Furthermore, the levels of Talin (a cytoskeleton
protein that directly interacts with the intracellular domain of
integrins and participates in actin filament assembly, and in cell
spreading/migration) showed to be decreased in Mjd siRNA-
treated cells by both immunoblotting and immunofluorescence
assays (Figure 7A, B, C). Alterations in the amounts of these
proteins (Figure 7D) suggest that the phenotypic alterations
Figure 3. Ataxin-3 regulates the protein levels of a5 and a7 integrin subunits. (A) The amounts of a5 and a7 integrin subunits were
determined by immunoblotting. Whole cell extracts of undifferentiated (Day -2 and Day 0) and differentiated cells (Day 1 to Day 5) were analyzed for
a5 and a7 integrin subunits and a-tubulin in mock and Mjd siRNA transfected cells. (B) Relative band density of a5 integrin, a7 integrin (A+B) and a7B
integrin subunits in each day (comparing with Day -2), and for each transfection condition. The results were normalized for a-tubulin and correspond
to the average of three independent transfections 6 SEM (error bars). (C) Ataxin-3 is not regulating the amounts of Itga5 and Itga7 transcripts. Mock
and Mjd siRNA transfected C2C12 cells at Day 0 and Day 1 of differentiation, show identical transcript levels of Itga5 and Itga7 that were measured by
real-time RT-PCR. The results were normalized for the Hprt1 gene and correspond to the mean of three independent transfections6 SEM (error bars).
* statistical significance p,0.05 using Student t-test.
doi:10.1371/journal.pone.0011728.g003
Ataxin-3 and Myogenesis
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observed in mATX3-depleted C2C12 cells might reflect a
dysregulation of specific integrin-mediated signaling cascades
leading to changes in cytoskeleton, cell adhesion and motility.
Discussion
Myogenesis is one of the best studied systems of cell
differentiation. The muscle, in particular the striated muscle, is
well known by its unique structure consisting of a very well
organized cytoskeleton that enables its characteristic contractile
function. However, the formation and maintenance of these
structures, as well as the entire event of myogenic differentiation
from MPCs into the final myofibers, are very dynamic processes
and require a high coordination between the synthesis, degrada-
tion and assembly of key proteins. Degradation of muscle proteins
occurs through several mechanisms but more importantly by the
UPS. The fast and time-specific regulation of protein levels by the
UPS, is crucial for muscle development [8]. Several key factors in
myogenesis are known to be regulated by the UPS, namely
myogenic factors, such as MyoD and Myogenin, and membrane
proteins, like b-catenin and integrins [8,10,13,14,15].
The human ATX3 protein possesses DUB activity, suggestive of
a role in the UPS [21,22,23,24,38]. In this study, we further
confirmed the orthology of the mouse Mjd gene by demonstrating
that mATX3 protein possesses DUB activity, similarly to other
ATX3 and josephin proteins [39,40]. mATX3 and other DUBs,
such as Usp22 [41], Usp2-45 and Usp2-69 [42] are expressed
during mouse embryonic development but little is known about
their physiological function in that process. Here, we were able to
show that ATX3 plays a role during muscle differentiation. Mouse
ATX3 is highly expressed in heart (not shown) and skeletal muscle,
both in the precursor structures (epithelial somite, dermomyotome
and early myotome) and in myogenic fibers, indicating that this
DUB might be involved in all stages of muscle development.
In this study, we focused on the involvement of mATX3 in the
early stages of myogenic differentiation. Mjd siRNA depletion in
C2C12 cells was shown to induce morphological alterations
(round shape), defects in cell-cell alignment, and fragmented
myosin-positive filements. This phenotype was specifically due to
mATX3 repression as the levels of other josephin domain-
containing homologue genes remained unchanged in Mjd siRNA
cells. Furthermore, no alterations in the amounts of MyoD were
found during the differentiation process, indicating that mATX3 is
not affecting the myogenesis pathway onset.
We found that the phenotype observed in the mATX3-depleted
cells is likely due to a decrease in the levels of both a5 and a7
integrin subunits, known to be important for proper muscle
differentiation. During muscle differentiation, integrins play
fundamental roles and are strictly regulated, presenting highly
specific expression patterns for each discrete phase of myogenesis
[43,44]. Mouse ATX3 was found to regulate the amount of these
two integrin subunits at the protein level given that their mRNA
levels remain unaltered in the mATX3-knock down cells. The fact
that the a7 integrin subunit levels remain low at late differentiation
stages, even when the amount of mATX3 was partially restored,
suggests that mATX3 might have an indirect effect over this
integrin subunit, probably affecting (in an irreversible manner) the
degradation of other proteins that control its up-regulation or
maintenance. In contrast, a5 integrin subunit levels paralleled
those of mATX3 in the Mjd siRNA-treated cells suggesting a more
direct regulation. Consistently with this biological interaction, the
a5b1 integrin and mATX3 in vivo expression patterns seem to
correlate in the myotome of E9.5 and E11.5 mouse embryos and
in C2C12 cells [34,43,45]. In this work, we have also shown that:
(1) mATX3 interacts with the a5 integrin subunit; (2) overexpres-
sion of mATX3 stabilizes a5 integrin subunit and increases its half-
life; and (3) the amount of ubiquitinated a5 integrin subunit
increases in mATX3-depleted cells when the proteasome is
inhibited. Our results, together with the fact that a5 integrin
subunit is degraded by the UPS (Kaabeche et al. 2005), lead us to
suggest that this integrin subunit might be a substrate of mATX3
Figure 5. GST-tagged mATX3 pull-downs a5 integrin subunit
from an embryo extract. Purified recombinant GST::mATX3 protein
was incubated with a whole protein extract from an E16.5 mouse
embryo. Recombinant GST alone was used as control. GST pulled down
samples were analyzed by immunoblotting, first with the anti-a5
integrin antibody, and then with the anti-GST antibody, following
stripping. Lane 2 corresponds to 10% of the input where a5 integrin
subunit can be detected as with a band of 130 KDa. Lane 4 shows that
GST-mATX3 was able to pull-down a5 integrin. Note that a band of
90 KDa was also detected, which might correspond to a cleaved
product of a5 integrin generated during the assay. None of the a5
integrin bands were detected in the controls (lanes 1 and 3: beads
alone or beads+GST, respectively).
doi:10.1371/journal.pone.0011728.g005
Figure 4. a5 and a7 integrin subunits are down-regulated in mATX3-depleted cells. Maximum projection of confocal z-series images of
double immuno-stained cells for mATX3 (1) and a5 or a7 integrin subunit (2). (A–D) C2C12 differentiated cells labeled with mATX3 (red) and a5
integrin subunit (green): at Day 1, mATX3-depleted cells are misaligned and exhibit reduced levels of mATX3 and a5 integrin subunit (B), compared
to controls (A); and at Day 3, the Mjd siRNA transfected cells still present lower amounts of mATX3 and a5 integrin subunit and considerable
misalignment (D) in comparison to controls (C). Note that the stronger reactivity for mATX3 in Mjd siRNA cells at Day 3 (D.1 vs B.1) is accompanied by
a similar increase in a5 integrin subunit reactivity (D.2 vs B.2,). (E–F) mATX3-depleted and differentiated cells at Day 3 labeled with mATX3 (green) and
a7 integrin subunit (red) show reduced levels of mATX3 and a7 integrin subunit (F) compared to controls (E). DNA was stained with DAPI (blue) as
shown in the overlay (3). Scale bars represent 10 mm.
doi:10.1371/journal.pone.0011728.g004
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DUB activity, which would act to prevent its UPS-mediated
degradation. Decreased levels of a5 integrin subunit in mATX3-
depleted cells might cause an alteration in the cell surface
molecules, and consequently an impairment of cell-cell and cell-
matrix interactions that might, in turn, lead to the observed
phenotypic changes of the mATX3-depleted C2C12 cells.
The proteomic profile of mATX3-depleted undifferentiated
C2C12 cells pointed to an involvement of the integrin signaling
transduction cascades.Three downstream targets implicated in the
actin cytoskeleton assembly and organization presented altered
levels: Cdc42, Arpc2 and Arpc3 (subunits of the Arp2/3 complex).
In mATX3-depleted cells, Arpc2, one of the core subunits of the
Arp2/3 complex, is down-regulated; this can lead to an
inappropriate assembly of this nucleation complex. The decrease
is Arpc2 is possibly due to a decrease of the integrin core signaling,
specifically of the a5 and a7 integrin subunit-containing receptors.
On the other hand, Arpc3 (Arp2/3 lateral subunit), as well as
Cdc42 (Rho-GTPase that activates Arp2/3-mediated actin
polymerization [46]) were upregulated. This could be a result of
the compensation by other types of integrin receptors, in an
attempt to overcome the dysregulation of the actin cytoskeleton.
Additionally, two other cytoskeleton-associated proteins, were
shown to be down-regulated: plectin1 (Plec1) and vimentin (Vim).
Interestingly, a6b4 integrin binds to Plec1 preventing its binding
to F-actin but not interfering with intermediate filament binding
[47]. In addition, vimentin also binds to Plec 1 in intermediate
filaments [48]. These alterations suggest that the cytoskeleton
structures in general may be deregulated in the absence of
mATX3, which may explain the altered morphologic features of
mATX3-depleted cells.
Cdc42 upregulation may also be due to the higher levels of
ARHGDIA, a Rho GDP dissociation inhibitor that is also an
ATX3 interactor [49], and is known to increase the translocation
of Cdc42 from membrane to cytosol [50]. The upregulation of
galectin-3 (Lgals3) is consistent with the high levels of Cdc42 since
the former is responsible for its activation via Cspg4 [51]. This
upregulation of Lgals3 may be an attempt to trigger other integrin
receptors in order to overcome a5b1 and a7b1 down-regulation at
Figure 6. Ataxin-3 stabilizes a5 integrin subunit and represses its proteolysis. (A) Effect of mATX3 overexpression in the half-life of a5
integrin subunit. C2C12 cells were transfected with the pEGFP:Mjd (GFP::mATX3), the pEGFP:MjdC14A (GFP::mATX3C14A) or the pEGFP-C1 (GFP)-
empty plasmids, and after 48 hrs cells were treated with cycloheximide for 0, 30, 60 or 180 min. Whole cell extracts were collected for these time
points and analyzed for the levels of endogenous a5 integrin subunit by immunoblotting. The overexpression of GFP::mATX3, but not the of GFP or
the catalytic mutant GFP::mATX3C14A, was shown to stabilize the levels of a5 integrin subunit. (B) The graph represents the relative amounts of a5
integrin subunit in GFP, GFP::mATX3 and GFP::mATX3C14A overexpressing cells at various cycloheximide treatment times. The levels of endogenous
mATX3 were similar in all the transfections. The results were normalized for a-tubulin and correspond to the average of three independent
transfections 6 SEM (error bars). (C) Denature-renature immunoprecipitation of a5 integrin subunit from Mjd siRNA, mock, GFP, GFP::mATX3, or
GFP::mATX3C14A transfected C2C12 cells treated with the proteasome inhibitor MG132 at 10 mM, during 12 h. The immunoprecipitated forms of a5
integrin subunit were separated in a SDS-PAGE gel and blotted for ubiquitin and a5 integrin subunit (low and high exposure of the same blot). An
increase of ubiquitinated forms of a5 integrin subunit was detected in mATX3-depleted cells. Cells overexpressing GFP::mATX3 showed a reduction in
ubiquitinated a5 integrin subunit forms. No decrease of these species was observed in cells overexpressing the catalytic mutant GFP::mATX3C14A.
doi:10.1371/journal.pone.0011728.g006
Ataxin-3 and Myogenesis
PLoS ONE | www.plosone.org 9 July 2010 | Volume 5 | Issue 7 | e11728
Figure 7. Ataxin-3 depletion affects the levels of proteins involved in the integrin signaling cascade which regulates cytoskeleton
organization, cell adhesion and motility. (A) The levels of Cdc42, Arpc2, Arpc3, Plec1 and Vim, were found to be altered in a proteomic analysis
of mATX3-depleted C2C12 cells (Day 0). These results were confirmed by immunoblotting of whole cell extracts of undifferentiated (Day 0) mock and
Mjd siRNA transfected cells. The levels of Talin were also found to be downregulated by immunoblotting analysis. (B) Fold change correspondent of
relative band density of each protein in Mjd siRNA transfected cells comparing with control cells. The results were normalized for a-tubulin and
correspond to the average of three independent transfections 6 SEM (error bars). (C) Maximum projections of confocal optical z-series images of
immunofluorescence staining for Talin (green) of undifferentiated mock or Mjd siRNA-transfected C2C12 cells (Day 0). DNA was stained with DAPI
(blue). Scale bars represent 10 mm. (D) Scheme of the proteins showing altered levels upon mATX3-depletion in C2C12 cells and related with the
integrin signaling pathway (based in the analysis performed with the Ingenuity Pathway AnalysisH software). Upregulated and downregulated
proteins found in the proteomic analysis, as well as a5 and a7 integrin subunits, are shown in red and green, respectively. Proteins with confirmed
altered levels by further immunoblotting and/or immunofluorescence are represented by full-surrounded lines, and the ones only identified as
altered in the proteomic analysis by dashed-surrounded lines.
doi:10.1371/journal.pone.0011728.g007
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the cell surface. Furthermore, the down-regulation of talins (actin
and integrin binding proteins) may explain per se the misalignment
and apparent failure of adhesion observed in the mATX3-depleted
cells given their key role in focal adhesions and cell spreading [52].
Taking all the evidence presented, ATX3 seems to be crucial for
the correct cell-cell interaction and alignment, required for cell
fusion and progression of myogenesis. However, in the recently
reported mATX3 knockout mouse [53], muscle malformations
were not described, suggesting that the phenotype presented by
the Mjd siRNA C2C12 cells (an isolated system) during particular
phases of myogenesis, might be overcome in a whole organism,
such as the mouse embryo. This could be possible by the
upregulation of partially redundant proteins, such as other mouse
josephins. Compensation phenomena were also suggested to
explain the lack of stronger phenotypes in some integrin knockouts
[54], and redundancy of myogenic regulatory factors is well known
in many animal models [55,56,57]. Nevertheless, specific muscle
studies in this knockout mouse model are still required to exclude a
muscle associated phenotype. Interestingly, recent work has shown
that at higher temperatures the C. elegans ataxin-3 knockout
animals have a severe motility defect, potentially correlated with
some muscle deficits [29].
Final remarks
Since the cloning of the MJD gene in 1994 [58], several cellular
and animal models of MJD have been developed but, until now, its
pathogenic mechanism remains unknown. Given that MJD is a
dominant disease, a gain of function of mutant ATX3 was
proposed as the cause of the pathogenesis. However, the
knowledge of the normal function(s) of ATX3 may also be
important for the unveiling of the pathogenic mechanism(s). Thus,
we could consider that in MJD patients sequestration of normal
ATX3 into the aggregates might lead to decreased levels of a5b1
and a7b1 integrin levels and, thereby, to an impairment of
myogenesis either during development or in adult MSCs, that
differentiate and give rise to new muscle fibers upon muscle injury,
possibly leading to the muscle atrophy seen in some type III MJD
patients [31,32]. More importantly, the a5b1 integrin, as a critical
regulator of the actin cytoskeleton, was shown to be very
important in the regulation of spine morphogenesis and synapse
formation in hippocampal neurons, presenting in this way a
fundamental role in synaptic plasticity [59]. Since an impairment
of synaptic transmission was reported in MJD transgenic C. elegans
[60], it will be interesting to know if integrins are playing a role in
this component of pathogenesis.
In summary, we report the physiological implication of the
DUB mATX3 in myogenesis through the regulation of the
integrin signaling transduction pathway. This is the first report of a
direct target of the mouse ataxin-3 DUB activity, and also the first
report of the involvement of a DUB in a developmental process.
This novel biological role of ataxin-3 opens the possibility that
ataxin-3 might play a similar function in neuronal differentiation
and could also be important for the understanding of the
pathogenic mechanism underlying MJD.
Materials and Methods
Antibodies
The primary antibodies used were: rabbit anti-ATX3 antise-
rum (kindly provided by H. Paulson), monoclonal antibody for
ubiquitinylated proteins (FK2, Biomol International LP), rabbit
anti-ubiquitin (Dako), anti-MHC (F59, DSHB), anti-myogenin
(F5D, DSHB), rabbit anti-MyoD (provided by J. Harris), rabbit
anti-a5 integrin subunit (Chemicon), goat anti-a5 integrin
subunit (Santa Cruz Biotechnology (SCB)), rat anti-a7 integrin
subunit (provided by A. Sutherland), anti-a-tubulin (clone AA4.3,
DSHB), goat anti-GST (GE Healthcare), rabbit anti-GFP (SCB),
anti-talin (C20, SCB), anti-Cdc42 (B8, SCB), anti-Arpc2 (C13,
SCB), anti-Arpc3 (H17, SCB), anti-plectin (10F6, SCB) and anti-
vimentin (DSHB). The peroxidase-conjugated secondary anti-
bodies used for immunoblotting were: goat anti-mouse (Santa
Cruz Biotechnology), goat anti-rabbit (Santa Cruz Biotechnolo-
gy), goat anti-rat (Serotec), and donkey anti-goat (Santa Cruz
Biotechnology). For double immunofluorescence assays, the
Alexa Fluor (AF) secondary antibodies (Molecular Probes) used
were the following: AF 488 goat anti-rabbit, AF 568 goat anti-
mouse, AF 594 goat anti-rat, AF 594 goat anti-rabbit, and AF488
donkey anti-rabbit.
Embryo collection and histology
All animal procedures were conducted in accordance with
European regulations (European Union Directive 86/609/
EEC). Animal facilities and the people involved in animal
experiments (MCC, FB) were certified by the Portuguese
regulatory entity - Direcc¸a˜o Geral de Veterina´ria. All the
protocols performed were approved by the joint Animal Ethics
Committee of the Life and Health Sciences Research Institute,
University of Minho. For embryonic expression studies, the day
of detection of a vaginal plug was designated as embryonic day
(E) 0.5. Pregnant C57Bl/6 (Harlan Interfauna Iberica, SA)
females were sacrificed by CO2 inhalation, and embryos from
E9.5, E11.5, E14.5, E15.5 and E18.5 stages were collected in
cold PBS. The embryos were fixed as previously described [43].
Embryos were cryosectioned in a Leica CM1900 cryostat into
15 mm- thick sagittal slices, which were collected on Super Frost
slides and stored at 220uC.
RNA interference
Dicer small interference RNA (siRNA) was prepared using the
Block-iTTM RNAi Topo transcription kit (Invitrogen) for topo-
mediated generation of templates and production of double-
stranded RNA (dsRNA), and the Block-ItTM Dicer RNAi kit
(Invitrogen) for the generation, purification of Mjd-specific d-
siRNA, using the manufacturer’s conditions. Briefly, we started to
generate an Mjd cDNA fragment by PCR, consisting in the first
(59-39) 646 bp, using primers mmMJD106/mmMJD10, the
pMjd1 plasmid as template, and the Platinum Taq DNA
Polymerase High Fidelity; this PCR product was processed using
the abovementioned kits to produce the Mjd d-siRNA.
C2C12 culture and transfection
Mouse C2C12 myoblasts were cultured in growth medium (GM)
containing Dulbecco’s modified Eagle’s (DMEM) Glutamax (Gibco
BRL), 20% fetal bovine serum (FBS) and 1% penicillin/streptomycin,
in a 5% CO2 humidified chamber at 37uC. To induce myogenic
differentiation, C2C12 cells at 80–100% confluence in GM where
washed with phosphate-buffered saline (PBS) and grown in
differentiation medium (DM) containing DMEM glutamax, 2%
horse serum and 1% penicillin/streptomycin, that was changed every
day. Mjd siRNA and mATX3 overexpression experiments consisted
in transfecting of 16105 C2C12 myoblasts per well (6-well plates)
with either 300 ng of Mjd siRNA and 2 mL of Lipofectamine 2000
(Invitrogen), or 2 mg of pEGFP:Mjd or pEGFP:MjdC14A and 5 mL
of Lipofectamine 2000 in antibiotic-free medium (Opti-MEM, Life
Technologies) for 6 hrs, after which the medium was changed for
GM. Mock transfections were also performed in the same way but
without siRNA, as well as transfections with the empty pEGFP-C1
vector (Clontech). At least, three independent experiments were
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performed. Regarding C2C12 differentiation, the day of transfection
was named Day -2 of differentiation. Two days after (Day 0) the GM
was changed for DM that was changed every day. Cellular extracts
were collected from Days 22, 0, 1, 2, 3, and 5 of differentiation.
Immunofluorescence staining
Slides containing the embryo slices from the several collected
stages were placed in a humified chamber and the tissues were
permeabilized in 0.2% Triton-X-100/PBS during 20 min, and
blocked in 10% goat serum during 30 min. For double staining
analysis, the slices were then incubated with the rabbit anti-
ATX3 antiserum (1:500) in conjunction with another primary
antibody (all diluted in 1% BSA/PBS) overnight at 4uC. For
immunofluorescence labeling, C2C12 cells were transfected after
being seeded in coverslips. At the differentiation days 0, 1, 3, and
5, cells were washed briefly with PBS and fixed with 1% PFA/
PBS, through 10 min, and permeabilized in 0.5% Triton-X-100/
PBS (5 min). After blocking in 2% BSA/PBS (30 min), coverslips
were incubated with the anti-ATX3 antiserum (1:500) in
combination with other primary antibody (all diluted in 2%
BSA/PBS) overnight, at 4uC. Primary antibodies used were
mouse anti-MHC (1:20), mouse anti-myogenin (1:20), goat anti-
a5 integrin subunit (1:100), rat anti-a7 integrin subunit (1:100),
and goat anti-talin (1:100).Subsequently, slices and coverslips
were washed with PBS and incubated for 1 h with the two
corresponding Alexa Fluor (AF) secondary antibodies, diluted
1:1000 in 1% BSA/PBS. After that, slices were stained with 49,6-
Diamidino-2-phenylindole dihydrochloride (DAPI, Sigma) dilut-
ed 1:2000 in PBS during 5 min, and mounted with Vectashield
(Vector Laboratories).
Imaging
Embryo sections and C2C12 cells processed for immunofluo-
rescence were photographed in an OLYMPUS IX 81 confocal
microscope using the software OLYMPUS Fluoview1000 (FV
viewer v.1.6.a). Optical z-series for both embryos and C2C12 cells
were used to obtain maximum projections. C2C12 cells were
photographed with a SONY digital camera coupled to a phase
contrast Axiovert 200 Zeiss microscope, during differentiation
after mock and Mjd siRNA transfections.
Quantitative real-time RT-PCR
C2C12 total RNA (2 mg) from differentiation Day 0 and Day 1
(mock, and Mjd siRNA transfections) was reverse transcribed using
the SuperScript First-Strand Synthesis System for RT_PCR
(Invitrogen) with an oligo(dT) primer. Gene amount was assessed
by quantitative real-time RT-PCR, using the QuantiTec SYBR
Green PCR kit (Qiagen), 2 mL of total cDNA, and 500 nM of
each primer. The pair of primers used to amplify the genes Itga5,
Itga7, Josd1, Josd2, and Hprt1 was respectively: Itga5(1)/Itga5(2)
(148 bp); Itga7(1)/Itga7(2) (151 bp); Josd1(1)/Josd1(2) (116 bp);
Josd2(1)/Josd2(2) (147 bp); and Hprt(3)/Hprt(4) (249 bp) (Table
S2). The reactions were carried out in a real-time cycler
LightCycler (Roche) using standard cyclic conditions indicated
in the abovementioned kit.
Protein synthesis inhibition
C2C12 cells were transfected with pEGFP:Mjd, pEGFP:
MjdC14A or pEGP-C1 plasmids as abovementioned. Forty eight
hrs after transfection, the medium was changed for DM. After
24 hrs, cells were treated with cycloheximide (Merck) at 50 mg/
mL during 30, 60, or 180 min. Whole protein extracts were
prepared from each experiment that was performed in triplicate.
Preparation of total cellular and tissue extracts
For total protein extraction, C2C12 cells from the differentia-
tion days 2 Day -2, Day 0, Day 1, Day 2, Day 3 and Day 5 2
were washed briefly with PBS and collected in 500 mL of cell lysis
buffer (1% Nonidet P-40, Complete (Roche Diagnostics) in PBS).
Total protein extract from a mouse E16.5 embryo was collected
after homogenization in 1 mL of tissue lysis buffer (0,25% Triton
X-100, Complete (Roche Diagnostics) in PBS), sonication, and
centrifugation. The total protein amount was quantified using the
Bradford reagent (Sigma Aldrich) and appropriate dilutions were
stored at 220uC. For total RNA extraction, cells from the
differentiation Day 0 and Day 1 were washed with PBS and after
centrifugation the cell pellet was stored at 280uC. Total RNA was
purified using the Versagene kit (Gentra Systems) according to the
manufacturer instructions.
GST pull-down and immunoprecipitation
For GST pull-down assay, the purified GST or GST-tagged
proteins (2 mg) (Materials and methods S1) were incubated
rotating with 40 mL of glutathione-sepharoseTM 4B beads (GE
Healthcare), in a final volume of PBS/protease inhibitors, during
1 h, at 4uC. Whole E15.5 embryo proteins extract (150 mg) was
added and incubated for 2 hrs, at 4uC, in a rotator. Beads were
washed four times with PBS and bound proteins were eluted in
65 mL of Laemmli sample buffer, at 95uC, for 5 min. Itga5 was
immunoprecipitated from cells using denature/renature immuno-
purification as previously described [24]. Briefly,5 mg of the anti-
a5 integrin subunit antibody (Chemicon), previously cross-linked
with protein G beads (Sigma),were incubated overnight, at 4uC
with 500 mg of total protein extracts of C2C12 cells from Day 1 of
differentiation subjected to 10 mM MG132 for 12 h.
Proteomics
iTRAQ labeling and trypsin digestion. Total protein
extracts were obtained from C2C12 cells from differentiation
Day 0 (mock, and Mjd siRNA transfections). After quantification,
100 mg of total proteins from each condition was precipitated
using six volumes of cold acetone to remove interfering substances.
The samples were incubated at 220uC for 1 h and then
centrifuged at maximum speed at 4uC. Protein pellet was
ressuspended in 40 mL of 500 mM triethyl ammonium
bicarbonate with 1% SDS, vortexed, and briefly sonicated until
fully dissolved. The proteins were reduced using 2 mL of 50 mM
tris-(2-carboxyethyl) phosphine for 1 h at 60uC, and cysteines were
blocked with 200 mM methyl methane thiosulfonate (MMTS) for
10 min at room temperature. Ten micrograms of Sequencing
Grade Modified Trypsin (Promega) diluted in water was added to
each sample and incubated overnight at 37uC. The iTRAQ
reagents (Applied Biosystems) were reconstituted in 70% ethanol,
transferred to the respective sample and allowed to incubate for
1 h. Reagent 114 was added to the Day 0 mock, and 115 to Day 0
Mjd siRNA; and the labeled peptides were then combined and
evaporated to dryness in a SpeedVac. Each sample was re-
dissolved in 50 mL of 0,1% trifluoroacetic acid (TFA) and desalted
using C18 empore disks.
Isoelectric focusing. Desalted samples were applied on a
13 cm IPG strip, pH 3–10 (GE Healthcare), rehydrated for 12 hrs
and then focused in a IPGphor using the following parameters:
hold at 500 V 1 h, linear gradient from 500–1000 V 15 min, hold
at 1000 V 1 h, linear gradient from 1000 V–8000 V 30 min, hold
at 8000 V 2 hrs. The strips were cut into 12 fractions and focused
peptides were extracted from the gel using a TFA gradient. The
sample were evaporated and desalted as mentioned above.
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Peptides were dissolved in 1% HCOOH just before LC-ESI-MS/
MS analyses.
LC-ESI-MS/MS analyses. Around 6–8 mg of peptides from
each fraction were analyzed using a nanoflow LC (Famos,
Switchos, and UltimatePlus; LC Packings - Dionex Corporation,
Sunnyvale, CA, USA) coupled to a QSTAR Pulsar i ESI-hybrid
Q-TOF tandem mass spectrometer (Applied Biosystems/MDS
Sciex, Toronto, Canada). Peptides were concentrated and desalted
on a precolumn (0.3X5mm C18 PepMap100, LC Packings), and
eluted at 200 nL/min by increasing concentration of acetonitrile
onto a self-packed C18 reverse phase column (75 mmX15 cm,
Magic 5 mm 100 A˚ C18, Michrom BioResources Inc.) A linear
90 min gradient from 98% solvent A (97.8% water, 2%
acetonitrile, and 0.2% formic acid) to 35% solvent B (95%
acetonitrile, 4.8% water, and 0.2% formic acid) was used. Data
from LC-MS/MS runs were converted to peak list files with the
Analyst QS software (version 1.1).
Data analysis and protein identification. MS/MS
spectra generated was analyzed using Protein Pilot (version 2.0,
Applied Biosystems/MDS Sciex) search engine running over a
Mus musculus database downloaded from NCBI. The default
search settings used for quantitative analysis and protein
identification were: trypsin cleavage with fixed MMTS
modification of cysteine, iTRAQ labeling and variable
methionine oxidation. We have considered only protein
identifications with .95% statistical confidence in Protein Pilot.
The quantification of the identified proteins was reported using
the 114 (Day 0 mock) tag as the control with bias correction. For
data analysis, a P-value,0.05 was considered for 115/114
comparison, and the expression ratio cut-off used was of 20%,
i.e. were considered the ratio values smaller than 0.8 and higher
than 1.2. Data analysis and molecular network pathways were
created using the trial version of the Ingenuity Pathways Analysis
Inc. 5.0 software, which in turn uses all the information known
for a specific gene/protein including the one from their
homologues in other species. The ratios were converted to fold
change values through the negative inverse (-1/x) for values
between 0 and 1, not affecting the values greater than 1.
Immunoblotting
Total proteins from the several C2C12 differentiation days
(20 mg) were resolved in appropriate SDS-PAGE polyacrylamide
gels and then transferred to a nitrocellulose membrane (Hybond-
C, GE Healthcare). Membranes were incubated, overnight at 4uC,
with primary antibodies: anti-ATX3 antiserum (1:5000), anti-
myogenin (1:50), anti-MyoD (1:1000), rabbit anti-a5 integrin
subunit (1:5000), anti-a7 integrin subunit (1:2000), anti-Arpc2
(1:1000), anti-Arpc3 (1:1000), anti-Cdc42 (1:1000), anti-plectin
(1:1000), anti-talin (1:1000) or anti-vimentin (1:1000). All mem-
branes were incubated with anti-a-tubulin (1:500) for loading
control. For the GST pull-down assays, bound proteins were
resolved in an 8% SDS-PAGE polyacrylamide gel and transferred
in the same abovementioned way. Blots were incubated with anti-
GST (1:7500) or rabbit anti-a5 integrin subunit (1:5000) overnight
at 4uC. The de-ubiquitination assays of the K48 and K63-
multiubiquitin chains were immediately loaded in a 10% SDS-
PAGE polyacrylamide gel, and transferred in the same above way.
Membranes were incubated with a 1:1500 dilution of a
monoclonal antibody to ubiquitinylated proteins. For the immu-
noprecipitation assay, bound proteins were separated in a regular
SDS-PAGE gel, and membranes were probed first with the anti-
ubiquitin antibody (Dako) (1:1000), and then with the rabbit anti-
a5 integrin subunit antibody (1:2000). Detection of the immuno-
complexes was performed using the peroxidase-conjugated
secondary antibodies anti-mouse (1:10000), anti-rabbit (1:10000),
anti-rat (1:10000), or anti-goat (1:30000), and a SuperSignal West
Pico Chemiluminescent Substrate (Pierce). The immunocom-
plexes signal was registered in ECL-films (Hyperfilm, GE
Healthcare), and after that quantified using the software Quantity
One 4.6.3 (Bio-Rad).
Statistical analysis
The relative mean band density for each analyzed protein, in at
least three independent immunoblottings, was compared between
two groups of experiments (mock- and siRNA- transfected cells)
using the t-test (calculated using the SPSS version 16.0 package).
The same approach was used to analyze real-time PCR data. A
significant value of p,0.05 was considered.
Supporting Information
Materials and Methods S1
Found at: doi:10.1371/journal.pone.0011728.s001 (0.02 MB
PDF)
Figure S1 The transcript levels of the genes encoding other
josephin-domain containing proteins Josd1, and Josd2 for mock
and Mjd siRNA transfected C2C12 cells at Day 0 and Day 1 of
differentiation, were measured by quantitative real-time RT-PCR,
and showed to be similar. The results were normalised for the
Hprt1 gene and correspond to the mean of three independent
transfections +/2 SEM (error bars).
Found at: doi:10.1371/journal.pone.0011728.s002 (0.09 MB
TIF)
Figure S2 Mouse ataxin-3 conserves the deubiquitinating
activity observed for the human ataxin-3. A) Scheme of the
recombinant His-tagged proteins used in this study: mATX3,
the full-length protein; mATX3:C14A, the full-length protein
carrying the C14A point mutation; mATX3:jos, the Josephin
domain of mATX3; mATX3:jos:C14A, the Josephin domain
with the C14A mutation; and mATX3:UIMs, the C-terminal of
mATX3 containing the three UIMs. B) Polyubiquitin immu-
noblotting showing the deubiquitinating activity of each used
protein. mATX3, as well as its Josephin domain for itself
(mATX3:jos) were able to cleave both K48 and K63-linked
polyubiquitin chains, preferentially with two or more ubiquitins.
The mutation of the catalytic cysteine in these two proteins
(mATX3:C14A and mATX3:jos:C14A) abolished their DUB
activity. The C-terminal of mATX3 containing the UIMs
(mATX3:UIMs) is not capable to hydrolyse polyubiquitin
chains.
Found at: doi:10.1371/journal.pone.0011728.s003 (0.60 MB
TIF)
Table S1 Proteins showing altered levels upon Mjd siRNA in
undifferentiated C2C12 cells (Day 0). Cut-off (sketched line):
proteins with fold changes $20% (1.2, ratio ,0.8) considering a
statistical significant p-value ,0.05. Functional networks: (A)
cellular movement; (B) drug metabolism; (C) protein synthesis; (D)
skeletal and muscular system development and function, tissue
morphology; (E) cellular development, embryonic development,
cellular assembly and organization; (F) small molecule biochem-
istry, gene expression.
Found at: doi:10.1371/journal.pone.0011728.s004 (0.06 MB
PDF)
Table S2 Primers used in this study.
Found at: doi:10.1371/journal.pone.0011728.s005 (0.02 MB
PDF)
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